TYRA Tyra Biosciences, Inc.
USHealthcareAs of 2026-07-08 16:00
Why TYRA matters now
Tyra Biosciences, Inc. (TYRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $32.57 with +1.97% on the session and $1.94B in market capitalization; recent performance reads 1-month -16.16% and YTD +7.72%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-39.3M, and EPS of $-0.64. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.1%.
The latest indexable market news headline is "TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $51.50; recent insider activity includes Rothenberg Stephen Michael filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.51
P/S
0.00
EV/EBITDA
-12.29
DCF Value
$1.18
FCF Yield
-6.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-42.7%
ROA
-31.8%
ROIC
-36.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-39.3M | $-0.64 |
| Q4 2025 | $0.00 | $-33.8M | $-0.57 |
| FY 2025 | $0.00 | $-119.9M | $-2.01 |
| Q3 2025 | $0.00 | $-29.9M | $-0.50 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$50.50
Target (Median)
$51.50
Target Range
$42.00 - $59.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.75
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.